Assembly Biosciences

ASMB

Market cap $581M

38.50 USD

+1.77

4.82%

At close Updated Nov 21, 4:00 PM EST

Pre-market

After hours

38.50

0.00

1 day

4.82%

5 days

1 month

35.52%

3 months

44.47%

6 months

183.3%

Year to date

124.49%

1 year

161.55%

5 years

-41.56%

10 years

-64.15%

About: Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Employees: 73

Healthcare Biotechnology